Alcon acquires LenSx

Article

In its continuing quest to play a part in every step of the cataract procedure Alcon is to acquire LenSx Lasers Inc., for $361.5 million in cash

In its continuing quest to play a part in every step of the cataract procedure Alcon is to acquire LenSx Lasers Inc., for $361.5 million in cash plus maximum contingent payments of $382.5 million based on future revenue targets being achieved and exceeded. The deal will be subject to the required regulatory approvals in the States.

LenSx developed the first femtosecond laser approved by the FDA for use in cataract surgery. In a press statement Stuart Raetzman, vice president, global marketing and area president for the USA said: “This complementary technology aligns with Alcon's strategic focus to help surgeons improve every step of the cataract procedure. The LenSx laser provides surgeons a new level of predictability and control over critical manual steps during cataract removal – making those steps more precise and reliable.”

Related Videos
J. Morgan Micheletti, MD, speaks at the 2024 ASCRS meeting
Dr William Wiley of Cleveland Eye Clinic, Northeast Ohio
Paul Harasymowycz, MD
© 2024 MJH Life Sciences

All rights reserved.